dc.creator | Anastasilakis, A. D. | en |
dc.creator | Goulis, D. G. | en |
dc.creator | Polyzos, S. A. | en |
dc.creator | Gerou, S. | en |
dc.creator | Koukoulis, G. | en |
dc.creator | Kita, M. | en |
dc.creator | Avramidis, A. | en |
dc.date.accessioned | 2015-11-23T10:22:10Z | |
dc.date.available | 2015-11-23T10:22:10Z | |
dc.date.issued | 2008 | |
dc.identifier | 10.1055/s-2008-1046787 | |
dc.identifier.issn | 0018-5043 | |
dc.identifier.uri | http://hdl.handle.net/11615/25536 | |
dc.description.abstract | Risedronate and teriparatide have opposite actions on the osteoblast-osteoclast dipole and are expected to influence the RANK/RANKL/ osteoprotegerin (OPG) system. We aimed to evaluate changes in serum OPG and RANKL after risedronate or teriparatide administration in postmenopausal osteoporotic women. Seventy-four postmenopausal Caucasian women (age 64.1 +/- 1.0 years) were studied. Women with osteopenia served as controls (group 1, n=30). Women with osteoporosis were randomly assigned to either risedronate 35 mg once weekly (group 2, n = 2 1) or teriparatide 20 mu g once daily (group 3, n=23) for six months. Blood samples for serum RANKL, OPG, N-terminal propeptide of type I collagen (P1NP), and C-terminal telopeptide of type 1 collagen (CTx) were obtained before treatment and three and six months after treatment. P1NP and CTx levels remained unchanged in group 1, decreased in group 2 (p<0.001), and increased in group 3 women (p<0.001) throughout the treatment. OPG levels remained unchanged while RANKL decreased gradually in all groups (p<0.001). There was no correlation between OPG or RANKL and PINP or CTx. Our data suggest that neither antiresorptive nor ostecianabolic therapy causes specific alterations of serum OPG/RANKL levels; therefore, these cytokines cannot substitute for the established markers of bone turnover in the monitoring of response to osteoporosis treatment. | en |
dc.source | Hormone and Metabolic Research | en |
dc.source.uri | <Go to ISI>://WOS:000254922400009 | |
dc.subject | osteoprotegerin | en |
dc.subject | RANKL | en |
dc.subject | teriparatide | en |
dc.subject | risedronate | en |
dc.subject | bone markers | en |
dc.subject | BONE-MINERAL DENSITY | en |
dc.subject | GLUCOCORTICOID-INDUCED OSTEOPOROSIS | en |
dc.subject | PARATHYROID-HORMONE (1-34) | en |
dc.subject | KAPPA-B LIGAND | en |
dc.subject | CIRCULATING OSTEOPROTEGERIN | en |
dc.subject | BIOCHEMICAL MARKERS | en |
dc.subject | RECEPTOR ACTIVATOR | en |
dc.subject | PAGETS-DISEASE | en |
dc.subject | AGE | en |
dc.subject | TURNOVER | en |
dc.subject | Endocrinology & Metabolism | en |
dc.title | Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: A randomized, controlled trial | en |
dc.type | journalArticle | en |